After a blood cancer diagnosis, a survivor reflects on the close friends who let her be herself and asks whether she is the kind of friend she once needed.
|Articles|June 5, 2013
From ASCO: Updates in HER2-positive breast cancers
Author(s)Debu Tripathy
Advertisement
Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.
Advertisement
Related to this article
From a new chemotherapy combination to the first RAS-targeted pill, here's what five years of pancreatic cancer approvals mean for patients.
Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.
A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.
In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient cancer.
Medicare will move ostomy supplies to six national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.
Advertisement
Advertisement
Trending on CURE
1
Precision Radiation Cuts 1-Year Pancreatic Cancer Recurrence to 20.2%
2
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
3
Urologic Oncologist Answers Top Searched Questions in Bladder Cancer
4
The Breast Cancer Test Many Patients Don’t Know to Ask For
5